| 8:00 - 16:00
|
|
Registration and Information Desk
Hall Symposia
|
| 8:30 - 10:30
|
|
Keynote 6: Latency and Reactivation
Symposia Auditorium
Presenter:
|
8:35-9:15
Felicia Goodrum Dartmouth College
Biography
Felicia Goodrum is a Professor in the Department of Microbiology and Immunology in the Geisel School of Medicine at Dartmouth. Dr. Goodrums work is focused on virus-host interactions and particularly those important for human cytomegalovirus to establish life-long latent infections and to make the decision to reactivate a program of replication. Dr. Goodrums work has been recognized through Leukemia and Lymphoma Society fellowships, the Howard Temin Award from the National Cancer Institute, the Pew Scholar in Biomedical Sciences Award, Kavli Young Investigators Award, the Presidential Award for Early Career Scientists and Engineers, and a National Institutes of Health MERIT award. She is past-President of the American Society for Virology and co-Editor in Chief for Journal of Virology. Dr. Goodrum is an active advocate for science, virology, and evidence-based decision making.
|
The puzzle of human cytomegalovirus latency and reactivation
The major focus of our research program is to understand the virus-host interactions that dictate outcomes of human cytomegalovirus (CMV) infection, particularly those important to viral latency and reactivation. CMV is a beta herpesvirus with a complex relationship with its host, infecting diverse cell types within the human host with varied patterns of infection. Cell type-specific interactions, particularly those following initial infection dictate the ability of the virus to replicate or establish latency following infection. We have identified viral genes important to latency and the mechanisms by which they function through defining the host pathways they target. Collectively, our work as explored virus-host interactions around homeostatic growth factor and stress signaling, innate responses to infection, and DNA damage and repair. A unifying theme of many interactions has been around virus control of vesicular trafficking to control signaling and the regulation of viral gene expression through hematopoietic cell differentiation. For example, we have shown that the virus controls the trafficking and signaling of the major homeostatic regulator, epidermal growth factor receptor (EGFR), with consequences for viral gene expression. Similarly, a viral protein critical for reactivation, UL136p33, is targeted for degradation by the host E3 ligase, inducible degrader of low-density lipoprotein receptor (IDOL), which is regulated by the liver X nuclear receptor signaling in a hematopoietic cell differentiation-dependent manner. The IDOL-induced instability of UL136p33 is critical for the establishment of latency and IDOL downregulation is important for reactivation. In addition, the PPAR nuclear receptor is also important for reactivation. Through these studies and others, a complex picture of latency and reactivation emerges whereby host factors control the expression and accumulation of viral gene products in a differentiation-specific manner, which allows the virus to sense and respond to changes in the host cell for maintaining latency or re-entering the replicative cycle.
|
|
| 8:30 - 10:30
|
|
Symposium 6A: Latency and Reactivation
Symposia Auditorium
Presenter:
|
9:15-9:40
Angus Wilson NYU School of Medicine
Biography
Angus Wilson is an Associate Professor at the New York University School of Medicine. He received his B.Sc. in Genetics from the University of St Andrews in Scotland and Ph.D. in Molecular Biology from Kings College London. As a Damon Runyon-Walter Winchell Fellow with Winship Herr at Cold Spring Harbor Laboratory he used POU-homeodomain proteins to explore mechanisms of promoter selectivity of transcription factors. This work culminated in the purification and gene cloning of host cell factor 1 (HCF-1), an obligate partner of the herpes simplex virus (HSV) trans-activator VP16. As a heterodimer composed of two subunits derived from the same large precursor, HCF-1 serves as an organizing subunit of chromatin-modifying complexes important for cell cycle regulation, pluripotency, and development. Studies by the late Tom Kristie and others showed how HCF-1 recruitment maintains viral immediate-early genes in transcriptionally permissive euchromatin. At NYU, Angus co-directs a joint lab with Professor Ian Mohr studying transcriptional and post-transcriptional control of gene expression through the prism of herpesvirus infection. In 2010 they published the first of a series of impactful studies on the molecular basis of HSV-1 latency and reactivation in primary neurons. These works revealed the direct involvement of conserved pathways responsible for neuronal homeostasis in response to physiological, genomic, and epi-transcriptomic insults, providing a link between the known triggers of reactivation and the molecules controlling viral gene transcription. Current projects in the Mohr/Wilson Lab focus on RNA modifications, mRNA localization, and ribosome dynamics as determinants of herpesvirus productive replication and latency.
|
Loss of m6A RNA Methylation Activates the Integrated Stress Response to Drive HSV-1 Reactivation
HSV-1 latency and reactivation are governed by host neuronal physiology, with stress-response pathways converging on regulators such as AKT, mTORC1, and DLK to reshape viral chromatin and control episomal gene expression. We now identify RNA methylation as an additional layer of this regulatory network. In a primary neuron latency model, disruption of the m6A pathway triggers productive HSV-1 reactivation. Inhibition, knockdown, or targeted degradation of the m6A methyltransferase METTL3 consistently induces reactivation and production of infectious virus. Mechanistically, METTL3 loss activates the integrated stress response (ISR), marked by eIF2alpha phosphorylation, ATF4 induction, and downstream transcriptional remodeling. Notably, reactivation is blocked by ISRIB or by inducible expression of the viral eIF2alpha phosphatase ICP34.5, demonstrating that ISR activation is required for this effect. These findings identify m6A regulation as a critical safeguard of HSV-1 latency and reveal how neuronal stress pathways are integrated to control herpesvirus persistence.
|
|
|
Symposium 6B: Latency and Reactivation
Symposia Auditorium
Presenter:
|
9:40-10:05
Yoshihiro Izumiya University of California Davis
Biography
Yoshi Izumiya is a Japanese scientist and a Professor at the University of California Davis School of Medicine. He graduated from the University of Tokyo with a PhD in Veterinary Microbiology, where he worked on the oncogenic mechanisms of Marek's disease virus under the supervision of Dr. Takeshi Mikami. He did postdoctoral work with Dr. Hsing-Jien Kung at the University of California Davis Comprehensive Cancer Center. Since then, he has enjoyed studying oncogenic herpesviruses at UC Davis. He recently served as a director of the Viral and Pathogen-associated Malignancy program at the UC Davis Comprehensive Cancer Center. His laboratory focused on developing therapeutics for KSHV-associated diseases by leveraging 25+ years of research on KSHV gene regulation. He also began working on the chromosomally integrated human herpesvirus 6. Other interests include developing mathematical models of dynamic protein-protein interactions and generating cancer therapeutics through studies on viral-host protein interactions. He is also a founder of the non-profit international KSHV association and VGN Bio, Inc.
|
Inflammatory priming defines reactivation competence of KSHV latency
Kaposis sarcoma-associated herpesvirus (KSHV) is associated with inflammatory diseases such as Kaposis sarcoma (KS) and KSHV-associated inflammatory cytokine syndrome (KICS), in which viral genomes are frequently detected within inflamed tissues. However, whether inflammation directly promotes viral replication remains unclear. Notably, clinical observations indicate that anti-inflammatory interventions can reduce KSHV viral load, suggesting a functional link between inflammatory signaling and viral propagation.
Here, we present a previously unrecognized role for inflammatory signaling in shaping KSHV infection through a temporally restricted priming mechanism. We show that pre-transduction of wild-type viral (v)IL-6, but not a signaling-defective cysteine mutant, establishes a transcriptionally permissive and epigenetically primed state that enables subsequent viral reactivation. In contrast, vIL-6 expression after the recombinant vIL-6Stop KSHV latency establishment fails to restore reactivation competence, indicating that vIL-6 does not function as a direct trigger but instead programs the viral genome during an early window of infection.
Mechanistically, this priming event defines the chromatin landscape of KSHV, enabling inducible expression of key viral genes, including the replication and transcription activator (RTA), while rendering the viral genome refractory once latency is established without prior priming. These findings indicate that reactivation competence is determined at the time of initial infection rather than by later inflammatory cues.
Together, our results support a model in which inflammatory microenvironments act not simply as drivers of viral replication, but as permissive niches that prime incoming viral genomes for future reactivation. This framework reconciles the preferential presence of KSHV-infected cells in inflamed tissues with the observed sensitivity of viral replication to anti-inflammatory therapies, and highlights a previously unappreciated role of inflammation in determining viral infection outcomes.
|
|
|
Symposium 6C: Latency and Reactivation
Symposia Auditorium
Presenter:
|
10:05-10:30
Renfeng Li University of Pittsburgh
Biography
Dr. Renfeng Li is an Associate Professor in the Department of Microbiology and Molecular Genetics at the University of Pittsburgh in Pittsburgh, Pennsylvania. He received his B.S. in Analytical Chemistry from Beijing University of Chemical Technology and his Ph.D. in Biology from Tsinghua University in 2008 under the mentorship of Dr. Sen-Fang Sui. He pursued postdoctoral training in Virology with Dr. Diane Hayward at Johns Hopkins University, focusing on Epstein-Barr virus (EBV) biology, and received additional NIH K99-supported advanced training in quantitative proteomics in Dr. Akhilesh Pandeys laboratory. For more than eighteen years, Dr. Li has been dedicated to EBV research, integrating biochemical, proteomic, and systems-level approaches to dissect virus-host interactions and epigenetic regulation of viral latency and reactivation. After serving on the faculty at Virginia Commonwealth University from 2014 to 2022, he joined the University of Pittsburgh in 2023. The Li lab focuses on elucidating the molecular and epigenetic mechanisms that control EBV latency and lytic reactivation, with the overarching goal of uncovering mechanistic vulnerabilities that can be targeted to develop therapies for EBV-associated malignancies.
|
The SUMO Grip: PIAS1-Driven Chromatin Remodeling Restricts EBV Reactivation
Epstein-Barr virus (EBV) establishes lifelong latency by maintaining its episome within host cell and tightly regulating viral gene expression. Our previous studies identified Protein Inhibitor of Activated STAT1 (PIAS1) as an EBV restriction factor that restricts lytic gene expression. However, the molecular mechanisms by which PIAS1 controls transcriptional silencing remain incompletely defined. By integrating quantitative proteomics, genomic editing, and functional genomics approaches, we demonstrated that PIAS1 restricts EBV reactivation through SUMOylation-dependent chromatin remodeling. We demonstrated that PIAS1-mediated SUMOylation promotes the assembly of repressive complexes containing BRMS1L and PHF23 on the EBV episome, facilitating its association with heterochromatin enriched for repressive histone marks. Disruption of PIAS1 or depletion of BRMS1L and PHF23, destabilizes this repressive complex, leading to enhanced viral lytic gene expression. Together, our findings support a model in which PIAS1-driven SUMOylation establishes a higher-order epigenetic hub that restricts EBV reactivation and maintains viral latency.
|
|
| 10:30 - 11:00
|
|
Refreshment Break
Foyer Mont-Royal + Foyer 3rd
|
| 11:00 - 12:30 - Concurrent Session
|
|
Concurrent Session 5A: Latency and Reactivation 2
International I/II
|
|
Concurrent Session 5B: Immunity and Vaccines 3
Cartier I/II
|
|
Concurrent Session 5C: Virus-Cell Interactions 4
Symposia Auditorium
|
| 12:30 - 13:30
|
|
Lunch
Foyer Mont-Royal + Foyer 3rd
|
| 13:30 - 15:00
|
|
Keynote 7: Oncogenesis
Symposia Auditorium
Presenter:
|
13:30-14:10
Paivi Ojala Translational Cancer Medicine Research program, University of Helsinki
Biography
Päivi Ojala is Professor of Cancer Cell Biology at Medicum, Faculty of Medicine, University of Helsinki, and a member of the Translational Cancer Medicine Research Program within the universitys Research Programs Unit. From 2013 to 2021, she served as Chair of Viral Tumorigenesis at Imperial College London, where she continues as a visiting professor. She earned her PhD in Molecular Genetics from the University of Helsinki in 1993 and completed postdoctoral training at Yale School of Medicine (199597) and the University of Helsinki (19972001).
Professor Ojala has made major contributions to the study of Kaposis Sarcoma herpesvirus (KSHV) and its mechanisms of tumorigenesis. Her research also investigates how the lymphatic endothelial microenvironment influences cancer cell metastasis and explores the development of CAR T‑cell therapies. Her group has extensive expertise in organotypic 3D co‑culture models, high‑content cell‑based screening, protein kinase signaling, and genomic viral technologies.
Her work has demonstrated that restoring p53 function with small‑molecule inhibitors represents a promising therapeutic strategy for KSHV‑induced lymphomas. She has also identified a developmental transcription factor as a key regulator of viral persistence and a potential therapeutic target. Her group showed that KSHV infection reprograms lymphatic endothelial cells (LECs) into a more invasive mesenchymal‑like state, revealing new insights into viral manipulation of endothelial identity.
|
KSHV-Driven Endothelial Chromatin Remodeling: Mechanistic Insights and Therapeutic Targets
Kaposis sarcoma (KS) is a highly vascular malignancy arising from lymphatic endothelial cells (LECs) and driven by infection with Kaposi sarcomaassociated herpesvirus (KSHV/HHV-8). Our work shows that developmental transcription factors (TFs) that establish lymphatic identity during embryogenesis become aberrantly reactivated in disease, where they impose pathological endothelial states. We found that KSHV recommissions the lineage-specific TF SOX18, a master regulator of lymphatic endothelial fate, to sustain high intracellular viral episome loads.
Our recent findings demonstrate that KSHV actively remodels host chromatin through a SOX18SWI/SNF axis, enabling the virus to persist within LECs. We identify SOX18 as a lineage-estricted pioneer factor that KSHV exploits to create a uniquely permissive chromatin landscape. This provides a mechanistic explanation for a long-standing question in the field: why LECsamong all endothelial subtypesuniquely support high KSHV episome burden.
Together, our data reveal that viral persistence depends on continuous, virus-directed chromatin remodeling, positioning KSHV not as a passive nuclear resident but as an active epigenetic regulator of the host genome. These insights show how an endothelial identity TF becomes a direct molecular interface between viral infection and oncogenic transformation, opening new therapeutic avenues for targeting KS at the level of chromatin regulation.
|
|
| 13:30 - 15:00
|
|
Symposium 7A: Oncogenesis
Symposia Auditorium
Presenter:
|
14:10-14:35
Rosemary Rochford University of Colorado, Anschutz Medical Campus
Biography
Rosemary Rochfords research program has focused extensively on the interplay between infectious diseases and cancer in sub-Saharan Africa. In 2024, she was received the Henle Award for major contributions to EBV research. Over two decades, her work has centered on the role of Epstein-Barr virus (EBV), malaria, and related viral co-infections in the development of pediatric cancers, particularly Burkitt lymphoma. Rochford expanded her research to another oncogenic herpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV). Her work in Kenya and Uganda has examined environmental and immunologic determinants of KSHV transmission, viral shedding, and seroconversion in children, as well as the impact of malaria and maternal HIV infection on early viral acquisition. These studies have contributed to our understanding infection-driven cancer risks in African populations. Rochford has also made important mechanistic contributions to the field, including identifying CD21 as a receptor for EBV entry into T cells and demonstrating how EBV type 2 infects T cells. Her group provided a link between EBV reactivation and malaria showing that heme can induce plasma cell differentiation and lytic reactivation. Her laboratory has investigated activation-induced cytidine deaminase (AID) expression, B-cell differentiation, antibody decay in infancy, and immune modulation during malaria infection, linking immunologic dysregulation to altered patterns of viral persistence and cancer susceptibility. Collectively, her sustained collaborative work has helped define the biological and epidemiological pathways connecting EBV, KSHV, and malaria with infection-associated malignancies.
|
Infection into Disease- What Drives Epstein-Barr Virus Oncogenesis
Epstein-Barr virus (EBV) exist as a life-long persistent infection in the majority of infected individuals worldwide. And yet, in a small percentage, EBV is associated with a number of human malignancies including Burkitt lymphoma (BL). This talk will focus on research from Rochfords group based on data obtained from pediatric clinical samples from our field site in Kisumu, Kenya where there is a high incidence of BL as well as analysis of B cells ex vivo and EBV+ B cell lines. The research addresses the question of how persistence of EBV is modulated by environmental exposure to a secondary pathogene.g. P. falciparum malaria. Could the lessons learned from studying the etiology of BL be used for understanding the etiology of other EBV associated malignancies and identify the underlying mechanisms driving infection into disease?
|
|
|
Symposium 7B: Oncogenesis
Symposia Auditorium
Presenter:
|
14:35-15:00
Karen Mossman McMaster University
Biography
Karen Mossman, Ph.D., obtained her HonBSc in Molecular Biology & Genetics at the University of Guelph (1992) and her PhD (1996) and PDF (2001) in Biochemistry and Molecular Virology, respectively, at the University of Alberta. She is currently a Professor in the Department of Medicine who has served as Chair, Department of Biochemistry & Biomedical Sciences (2013-2017), Associate Vice President Research (2017-2018) and Vice President Research (2018-2024) at McMaster University, Canada. Dr. Mossman is a Fellow of the Canadian Academy of Health Sciences and the American Association of Microbiology, was recognized by the Womens Executive Network as a Top 100 Canadas Most Powerful Women and received the 2024 Honorary Lifetime Membership Award from the International Cytokine and Interferon Society. Dr. Mossman has published over 160 peer-reviewed scientific publications and has contributed as author and editor to numerous books, including virology textbooks.
Dr. Mossman joined McMaster University in 2001, with a research focus on understanding the interactions between viruses and their hosts, both in normal healthy cells and in cancer cells, with the goal of developing novel therapy approaches for emerging viral infections and cancer. She is currently working with industry to develop Bovine herpesvirus type I as a clinical oncolytic viral cancer immunotherapy. At the start of the pandemic, her group helped isolate SARS-CoV-2 from Canadian patients which enabled COVID-related studies across the country. To better understand future pandemics, Dr. Mossmans lab studies bats and why bats are able to host a wide variety of viruses without getting sick.
|
Oncolytic Bovine Herpesvirus: a Surprising and Curious Immunotherapeutic
Oncolytic viruses (OVs) are a promising approach for cancer therapy as they selectively infect and kill transformed cells by exploiting mutations and alterations accumulated during transformation. While the selective replication of OVs within tumor cells was historically credited for their tumor-killing effects, induction of host anti-tumor immunity plays a significant role. OVs can modulate the tumor micro-environment to turn immune cold tumors hot, inducing immunogenic cell death (ICD) and sensitizing tumors to immune checkpoint inhibitors (ICIs).
The first FDA-approved OV was based on HSV-1. As a human pathogen, HSV-1 is predicted to be limited clinically by neutralizing antibodies; we thus opted to study the highly related alpha-herpesvirus bovine herpesvirus type-1 (BoHV-1). Within the NCI60 human cancer panel, 72% are targeted by BoHV-1 vs 32% for HSV-1. BoHV-1 does not cause disease in humans, is not neutralized by human serum, targets bulk & cancer-initiating cells regardless of mutational status or receptor expression but preferentially targets KRAS-mutated lesions (e.g. pancreatic, lung, colorectal). Unlike HSV-1, BoHV-1 alone is sufficient to induce ICD, sensitizing tumors to ICI.
While current dogma suggests OV replication is a critical component of efficacy, we have found that oncolytic BoHV-1 does not require replication for its in vivo efficacy. Moreover, systemic administration works as efficiently as direct intratumoral administration, even in the context of a robust neutralizing antibody response. New findings on oncolytic BoHV-1 will be discussed in this presentation.
|
|
| 15:00 - 15:30
|
|
Refreshment Break
Foyer Mont-Royal + Foyer 3rd
|
| 15:30 - 16:10
|
|
Bernard Roizman Lecture
Symposia Auditorium
Presenter:
|
15:30-16:10
Noam Stern-Ginossar Weizmann Institute of Science
Biography
Noam received her Ph.D. from the Hebrew University of Jerusalem, where she studied viral immune evasion and the functions of virally encoded miRNAs. She conducted her postdoctoral training with Jonathan Weissman at UCSF, pioneering the use of ribosome profiling to define the coding capacity of viruses. Since 2014, she has been a faculty member in the Department of Molecular Genetics at the Weizmann Institute of Science. Her research focuses on deciphering the molecular strategies herpesviruses use to regulate gene expression, establish latency, and reprogram host cellular pathways during infection.
|
Decoding HCMV Infection: Lessons from High Throughput Biology
Human cytomegalovirus (HCMV) establishes lifelong infection and exhibits remarkably complex interactions with its host, resulting in diverse infection outcomes ranging from productive replication to long-term persistence. Over the past decade, advances in high throughput technologies have transformed our ability to study these processes at unprecedented resolution. In this lecture, I will highlight how quantitative and genome scale approaches are reshaping our understanding of HCMV biology. I will discuss how ribosome profiling uncovered previously unrecognized complexity in the viral coding capacity and provided new insights into the regulation of viral gene expression. I will then describe the development of a viral centric functional genomic approach, termed VECOS, and describe our efforts to use it to systematically dissect host and viral factors controlling distinct stages of the viral life cycle. Finally, I will present how bulk and single cell RNA sequencing have revealed the remarkable heterogeneity of HCMV infection dynamics, helping to start addressing questions regarding infection outcomes, latency and viral persistence.
Together, these studies illustrate how high throughput technologies are transforming our ability to investigate complex virus host interactions and uncover fundamental principles governing HCMV biology.
|
|
| 16:10 - 16:20
|
|
Closing Remarks
Symposia Auditorium
|
| 16:20 - 16:25
|
|
Handover to IHW 2027
Symposia Auditorium
|
| 18:00 - 23:59
|
|
Banquet
Offsite
|